Published in Cancer Weekly, July 5th, 2005
Study 1: The response and resistance of BCR-ABL-positive leukemia to imatinib treatment was evaluated.
According to a study from Germany, "The advent of imatinib has considerably changed the treatment of chronic myeloid leukemia (CML). Early studies demonstrated high rates of hematologic and cytogenetic responses in all phases of the disease after limited observation periods."
T. Lahaye and colleagues from the University of Heidelberg "evaluated long-term outcome, rates of response, and resistance in 300 patients with BCR-ABL-positive leukemias (CML in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly